GREEN CROSS
Green Cross continues to build on a long legacy of providing life-saving and life-sustaining specialty therapeutics. Their bioscience division began its business in 1971 as producing plasma-derived biotherapies for the first time in Korea. For more than 40 years, they have specialized in providing biotherapeutics to improve the quality of life for people with rare and serious diseases worldwide. Their vaccine business develops and produces paediatric and adult vaccine against a broad range of in... fectious diseases, from worldโs 3rd hepatitis B vaccine to quadrivalent influenza vaccine. With their mission to improve health and well-being of people around the world, they have gone down a path that nobody wishes to explore. Their extensive research and development of innovative medicines that support treatment and prevention as well as cures for diseases in a wide range of therapeutic areas demonstrate their ongoing commitment to all people who rely on their products.
GREEN CROSS
Social Links:
Industry:
Biotechnology Health Care Sustainability
Founded:
1969-11-01
Address:
Yongin, Ch'ungch'ong-namdo, South Korea
Country:
South Korea
Website Url:
http://www.greencross.com
Total Employee:
1001+
Status:
Active
Contact:
+82312609300
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Content Delivery Network Font Awesome Domain Not Resolving Apache Mobile Non Scaleable Content
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2016-05-08 | HALO BioSynthesis Laboratories | HALO BioSynthesis Laboratories acquired by Green Cross | N/A |
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2020-10-12 | Kanaph Therapeutics | Green Cross investment in Series B - Kanaph Therapeutics | 21 M USD |
2018-11-20 | Vuno | Green Cross investment in Series B - Vuno | 12 M USD |
2018-11-20 | Genoplan | Green Cross investment in Series B - Genoplan | 1000 K USD |
2018-06-29 | Genoplan | Green Cross investment in Series B - Genoplan | 14 M USD |
2015-05-12 | Juventas Therapeutics | Green Cross investment in Series B - Juventas Therapeutics | 13.5 M USD |
2013-11-20 | Argos Therapeutics | Green Cross investment in Series E - Argos Therapeutics | 17.5 M USD |
2009-09-16 | PharmAbcine | Green Cross investment in Series A - PharmAbcine | 6 M USD |
Official Site Inspections
http://www.greencross.com Semrush global rank: 2.63 M Semrush visits lastest month: 6.56 K
Unable to get host informations!!!